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motion (ROM) and function at ﬁrst month, according with the
Knee System Score. Mean values, standard deviation, frequencies
and ANOVA tests for quantitative and chi-squared for qualita-
tive variables were calculated, by using a licensed SPSS package.
RESULTS: There were no differences in epidemiologic data
between groups. In group A, the total mean cost of TKA was
5.390€. The length of stay was 3.32 days, pain at ﬁrst month
37.8 points; ROM 84.32° and function 33.22 points. In group B,
total costs turned out to be 5.557€. The length of stay was 3.42
days, postoperative pain 41.97 points; ROM 89.08° and func-
tion 33.33 points. A cost-effectiveness ratio calculated for ability
to walk and pain slightly favoured group B (186.45 and 180.07
vs. 191.38 and 205.88, respectively). CONCLUSION: Despite
the theoretical advantages of a knee system design combined
with an additional reinforcement of the anaesthetic procedure,
only a slight improvement in cost-effectiveness in terms of pain
and function at ﬁrst postoperative month is evidenced.
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OBJECTIVES: The aim of this study was to estimate the incre-
mental cost-effectiveness ratio (ICER) of the use of antibodies
against cyclic citrullinated peptides (aCCP) in the very early
diagnosis of rheumatoid arthritis (RA). METHODS: Using a
decision analytic model and a published Markov model the 10
year progression of RA in patients ﬁrst diagnosed as undifferen-
tiated arthritis (UA) was modelled. Based on this model incre-
mental costs and QALYs of using aCCP additionally to ACR
criteria for diagnosing RA early were estimated. The effect of
delayed diagnosis and treatment due to the non-use of aCCP was
modelled as increased progression of the health assessment ques-
tionnaire (HAQ). For calculating QALYs, utilities were assigned
to HAQ-states. Uncertainty was analysed by univariate and
probabilistic sensitivity analyses (Monte-Carlo-Simulation).
RESULTS: Baseline ICER was 930 Euro/QALY. Univariate sen-
sitivity analyses identiﬁed the effect of later diagnosis on HAQ
progression as major source of uncertainty resulting in an ICER
range from “dominance” to 153,092 Euro/QALY, whereas
maximum ICER was 4870 Euro/QALY for all other variables.
Monte Carlo simulation resulted in a 95%-uncertainty interval
from –3537 Euro/QALY to 5429 Euro/QALY. When indirect
costs were considered, baseline ICER was –49.970 Euro/QALY
and Monte Carlo simulation resulted in a 95%-uncertainty inter-
val from –78,115 Euro/QALY to –23,444 Euro/QALY. CON-
CLUSION: Compared to the use of ACR-criteria alone, the
additional use of aCCP in the very early diagnosis of RA in
patients diagnosed as UA is likely to be a cost-effective strategy.
In particular when indirect costs are considered, the use of aCCP
seems to be a cost saver from a societal perspective. Nevertheless
there is a clear need for more research relating to the protective
effects of an early or very early diagnosis and treatment of RA on
the long-term progression of RA and resulting functional impair-
ment as measured by the HAQ.
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OBJECTIVES: To assess the cost-effectiveness of leﬂunomide
monotherapy versus cyclosporin monotherapy in metothrexate-
resistant rheumatoid arthritis from the perspective of National
Health Fund in Poland. METHODS: A decision analytic model,
based on framework proposed by Kavanaugh was developed. A
systematic review was conducted to collect clinical efﬁcacy data.
Indirect comparison with placebo as a common comparator was
performed. Direct medical costs including costs of drugs, therapy
monitoring, adverse reactions treatment, hospitalizations due
to progression of arthritis were analyzed. Because of short,
6-months time horizon, discounting was not performed (values
in Polish zloty (PLN): 1 Euro = 3.8 PLN). Univariate sensitivity
analysis was conducted for key clinical and cost variables.
RESULTS: Leﬂunomide and cyclosporin based strategies resulted
in 0.449 ACR20 and 0.323 ACR20 response, with correspond-
ing costs of 2740 PLN and 2730 PLN, respectively (cost-
effectiveness ratios were 6106 PLN/ACR20 and 8453 PLN/
ACR20, respectively). Switching from cyclosporin to leﬂunomide
based therapy resulted in additional ACR20 response gain for the
price of 81 PLN. One-way sensitivity analysis revealed that clini-
cal efﬁcacy reduction of 25% for leﬂunomide and increase of
25% for cyclosporin resulted in incremental cost-effectiveness
ratio rise to 3548 PLN/ACR20 and 6106 PLN/ACR20, respec-
tively. CONCLUSION: In case of methotrexate resistance,
leﬂunomide monotherapy is more cost-effective than cyclosporin
monotherapy from the perspective of Polish National Health
Fund.
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OBJECTIVES: To systematically review the current cost-
effectiveness literature of biological disease-modifying antirheu-
matic drugs (bDMARDs) in rheumatoid arthritis and to explore
reasons for differences in results. METHODS: Medline, Embase,
BIOSIS, Derwent Drug File, Cochrane library and NHS-EED
were searched on 12th March 2007 for studies published from
2002–2007. Full economic analyses of bDMARDs were included
after a two-stage review process. Bibliographies of included
studies were searched for additional citations. RESULTS: Nine
hundred and nine unique citations were retrieved, and 18 studies
met our criteria. Six analyses were carried out in the UK, 5 in the
US, 4 in Sweden, 2 in Canada and 1 in The Netherlands and
Japan. One of the 18 studies included both UK and Swedish
analyses. Nine studies assessed the cost-effectiveness of at least 2
bDMARDs, including etanercept, inﬂiximab, adalimumab and
anakinra; while the other 9 compared a single bDMARD with
standard DMARDs (e.g. methotrexate, MTX). Three studies
compared the cost-effectiveness of inﬂiximab plus MTX versus
MTX alone, and 6 estimated the cost-effectiveness of etanercept
compared with standard DMARDs. Decision modelling was
used in 16 studies. The 3 analyses that compared inﬂiximab plus
MTX with MTX alone (2 based on the same decision model)
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